Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVAC-HIV vCP1452 and Intermittent ART Withdrawal in HIV
NCT00011011Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2001
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ALVAC-HIV vCP1452 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2001; status: completed.
02
Drugs
ALVAC-HIV vCP1452
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00011011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00011011.